2-(6,7-dihydro-5H-cyclopenta[f][1]benzofuran-3-yl)-N-(5-methyl-1,3-thiazol-2-yl)acetamide | 790245-61-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并呋喃
• 英文名称: 2-(6,7-dihydro-5H-cyclopenta[f][1]benzofuran-3-yl)-N-(5-methyl-1,3-thiazol-2-yl)acetamide
• CAS: 790245-61-3
• 化学式: C₁₇H₁₆N₂O₂S
• 分子量: 312.4
• InChiKey: IELCYEUTXLYDOV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  22
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  83.4
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• [EN] BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY<br/>[FR] AMIDES DE BENZOFURANE ET LEURS ANALOGUES HÉTÉROAROMATIQUES DESTINÉS À ÊTRE UTILISÉS EN THÉRAPIE
  申请人：EUROPEAN MOLECULAR BIOLOGY LABORATORY

  公开号：WO2018229193A1

  公开（公告）日：2018-12-20

  The present invention relatesto a pharmaceutical composition comprising acompound of the formula Ias described belowor a tautomeror a pharmaceutically acceptable salt thereof; to the compound of the formula Ias described below or a tautomer or a phar- maceutically acceptable salt thereof for use as a medicament, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization, and to certain novel compoundsof the formula Ias described below or a tautomer or a pharmaceuti- cally acceptable salt thereof. Formula (I) wherein X1 is CR1 or N; X2 is CR2 or N; X3 is CR3 or N; X4 is CR4 or N; with the proviso that at most two of X1, X2, X3 and X4 are N; L1, L2 are a bond or a bivalent radical such as C1-C6-alkylene or C3-C8-cycloalkylene; A is 3-, 4-, 5-, 6-, 7- or 8-membered saturated, partially unsaturated or maximally unsaturated carbocyclic ring which may carry one or more substituents R9; or L2-A forms a group C1-C6-alkylene-OR13, C1-C6-alkylene-SR14 or C1-C6-alkylene-NR15R16; and R1, R2, R3, R4, R5, R6, R9, R13, R14, R15 and R16 are as defined in the claims and the description.

  本发明涉及一种药物组合物，包括下述的化合物I的构造或其互变异构体或药用盐；以及用作药物的下述的化合物I的构造或其互变异构体或药用盐，特别用于治疗或预防从炎症性疾病、过度增殖性疾病或紊乱、缺氧相关病理和以过度血管生成为特征的疾病中选择的疾病或紊乱；以及下述的某些新型化合物I的构造或其互变异构体或药用盐。其中，化合物(I)中X1为CR1或N；X2为CR2或N；X3为CR3或N；X4为CR4或N；但X1、X2、X3和X4中最多有两个为N；L1、L2为键或类似C1-C6-烷基或C3-C8-环烷基的二价基团；A为3-、4-、5-、6-、7-或8-成员饱和、部分不饱和或最大不饱和的碳环，可能携带一个或多个取代基R9；或L2-A形成一个基团C1-C6-烷基-OR13、C1-C6-烷基-SR14或C1-C6-烷基-NR15R16；而R1、R2、R3、R4、R5、R6、R9、R13、R14、R15和R16如权利要求和说明中所定义。
• BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY
  申请人：European Molecular Biology Laboratory

  公开号：EP3638664A1

  公开（公告）日：2020-04-22
• BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY
  申请人：European Molecular Biology Laboratory

  公开号：US20200216434A1

  公开（公告）日：2020-07-09

  The present invention relates to benzofuran ureas or carbamates of formula I and heteroaromatic analogues thereof as described below or a tautomer or a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing these compounds, and to these compounds for use in therapy, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization. Formula (I) wherein X 1 is CR 1 or N; X 2 is CR 2 or N; X 3 is CR 3 or N; X 4 is CR 4 or N; with the proviso that at most two of X 1 , X 2 , X 3 and X 4 are N; E 1 is O or NR 6a ; E 2 is O or NR 6b ; with the proviso that E and E 2 are not simultaneously O; L 1 is a bond, optionally substituted C 1 -C 6 -alkylene or C 3 -C 8 -cycloalkylene; L 2 is a bond, optionally substituted C 1 -C 6 -alkylene, C 3 -C 8 -cycloalkylene, etc.; A is 3-, 4-, 5-, 6-, 7- or 8-membered saturated, partially unsaturated or maximally unsaturated carbocyclic ring or a 3-, 4-, 5-, 6-, 7- or 8-membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring; or L 2 -A forms a group C 1 -C 6 -alkylene-OR 13 , C 1 -C 6 -alkylene-SR 14 or C 1 -C 6 -alkylene-NR 15 R 16 ; and R 1 , R 2 , R 3 , R 4 , R 5 , R 6a , R 6b , R 13 , R 14 , R 15 and R 16 are as defined in the claims and the description.
• BICYCLIC HETEROAROMATIC AMIDE COMPOUNDS FOR USE IN THERAPY
  申请人：European Molecular Biology Laboratory

  公开号：US20200216435A1

  公开（公告）日：2020-07-09

  The present invention relates to compounds of the formula I as described below or a tautomer or a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing such compounds; and to said compounds of the formula I or a tautomer or a pharmaceutically acceptable salt thereof for use as a medicament, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization, wherein X 1 is CR 1 or N; X 2 is CR 2 or N; X 3 is CR 3 or N; X 4 is CR 4 or N; Y 1 is N, NR 5a , S, O or CR 5b ; Y2 is N, NR 5c , S, O or CR 5d ; Z is N or C; with the proviso that at most two of X 1 , X 2 , X 3 and X 4 are N; with the proviso that Y 1 is not O if Y2 is CR5d and simultaneously Z is C; with the proviso that Y 1 and Y 2 are not both simultaneously O or S; with the proviso that at least one of Y 1 , Y 2 and Z is a heteroatom or heteroatom-containing group; L 1 is a bond, optionally substituted C 1 -C 6 -alkylene or C 3 -C 8 -cycloalkylene; L 2 is a bond, optionally substituted C 1 -C 6 -alkylene, C 3 -C 8 -cycloalkylene etc.; A is 3-, 4-, 5-, 6-, 7- or 8-membered optionally substituted, saturated, partially unsaturated or maximally unsaturated carbocyclic or heterocyclic ring; or L 2 -A forms a group C 1 -C 6 -alkylene-OR 13 , C 1 -C 6 -alkylene-SR 14 or C 1 -C 6 -alkylene-NR 15 SR 16 ; and R 1 , R 2 , R 3 , R 4 , R 5a , R 5b , NR 5c , R 5d , R 6 , R 13 , R 14 , R 15 and R 16 are as defined in the claims and the description.
• BICYCLIC HETEROAROMATIC UREA OR CARBAMATE COMPOUNDS FOR USE IN THERAPY
  申请人：European Molecular Biology Laboratory

  公开号：US20210147405A1

  公开（公告）日：2021-05-20

  The present invention relates to bicyclic heteroaromatic urea or carbamate compounds of formula I where the variables are as defined in the claims and the description. The invention moreover relates to a pharmaceutical composition containing these compounds I, and to these compounds for use in therapy, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization.